 |
Prospector
Profile
07.1500
|
| |
| Advaxis, Inc. |
NAICS |
541710 |
| The Technology Centre of New Jersey, Suite 117
North Brunswick, NJ 08902 |
Description |
Biotechnology |
| (732) 545-1590 |
Employees |
9 |
| http://www.advaxis.com/ |
Revenue |
(mil) |
0.4310 |
| |
Income |
(mil) |
-6.1970 |
| |
Assets |
(mil) |
4.0000 |
| |
Liability |
(mil) |
7.7090 |
| |
(for the year ended 2006-10-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Avaxis, Inc. reported a net loss of $2,054,459 on revenues of $154,201 for the six months ended June 30, 2007, which is lower than the net loss of $2,448,036 on revenues of 397,312 reported during the six months ended June 30, 2006. As a result of its recurring losses, the Company has an accumulated deficit of $11,716,633 and stockholder's deficit of $4,234,831 in its June 30, 2007 balance sheet. It also has strained liquidity with $159,276 in total current assets available to pay $1,496,834 in total current liabilities.
|
| |
|
Intellectual Property:
On July 1, 2002, the Company entered into a 20-year exclusive worldwide license and a right to grant sublicenses pursuant to license agreement with the University of Pennsylvania. Dr. Yvonne Paterson and the University of Pennsylvania have invested significant resources and time in developing a broad base of intellectual property around the cancer vaccine platform technology. The University of Pennsylvania currently has 11 issued and 15 pending patents in the United States and other countries including Japan, Canada, Israel, Australia, and the European Union, through the Patent Cooperation Treaty (PCT) system. These patents will allow the Company to take a strong lead in the field of Listeria-based therapy. [SEC 10-KSB 02-13-07]
|
| |
|
Description:
The Company engages in the research and development of new cancer-fighting techniques.
|
| |
|
Officers:
Thomas Moore (Chair & CEO); Dr. John Rothman (VP); Fred Cobb (VP & CFO); Dr. James Patton (Dir.); Roni A. Appel (Dir.); Dr. Thomas McKearn (Dir.); Richard Berman (Dir.); Martin R. Wade III (Dir.)
|
| |
|
Auditor:
Goldstein Golub Kessler LLP
|
| |
|
Securities:
Common Stock-Symbol ADXS.OB; OTC BB;
46,059,830 common shares outstanding as of July 31, 2007.
|
| |
| |
| |
| return to main page |
|
|
